Preclinical pharmacology, efficacy, and safety of varenicline in smoking cessation and clinical utility in high risk patients

References

• Cigarette smoking among adults, United States 2006MMWR Morb Mortal Wkly Rep2007561157116117989644
   PubMedGoogle Scholar
• 2008 PHS Guideline Update Panel, Liaisons, and StaffTreating tobacco use and dependence: 2008 update US Public Health Service Clinical Practice Guideline executive summaryRespir Care2008531217122218807274
   PubMed Web of Science ®Google Scholar
• Smoking-attributable mortality, years of potential life lost, and productivity losses, United States 2000–2004Morb Mortal Wkly Rep20085712261228
   Google Scholar
• EtterJFCytisine for smoking cessation: a literature review and a meta-analysisArch Intern Med20061661553155916908787
   PubMed Web of Science ®Google Scholar
• HaysJTEbbertJOSoodAEfficacy and safety of varenicline for smoking cessationAm J Med20081214 Suppl 1S32S4218342165
   PubMed Web of Science ®Google Scholar
• GarrisonGDDuganSEVarenicline: a first-line treatment option for smoking cessationClin Ther20093146349119393839
   PubMed Web of Science ®Google Scholar
• GoldbergSRSpealmanRDGoldbergDMPersistent behavior at high rates maintained by intravenous self-administration of nicotineScience19812145735757291998
   PubMed Web of Science ®Google Scholar
• JonesSSudweeksSYakelJLNicotinic receptors in the brain: correlating physiology with functionTrends Neurosci19992255556110542436
   PubMed Web of Science ®Google Scholar
• DaniJABiasiMDCellular mechanisms of nicotine addictionPharmacol Biochem Behav20017043944611796143
   PubMed Web of Science ®Google Scholar
• Le NovèreNCorringerPJChangeuxJPThe diversity of subunit composition in nAChRs: evolutionary origins, physiologic, and pharmacologic consequencesJ Neurobiol20025344745612436412
   PubMedGoogle Scholar
• McGeheeDSRoleLWPhysiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neuronsAnnu Rev Physiol1995575215467778876
   PubMed Web of Science ®Google Scholar
• WonnacottSPresynaptic nicotinic ACh receptorsTrends Neurosci19972092989023878
   PubMed Web of Science ®Google Scholar
• ClarkePBPertAAutoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neuronsBrain Res19853483553584075093
   PubMed Web of Science ®Google Scholar
• ZhouFMWilsonCDaniJAMuscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systemsNeuroscientist20039233612580337
   PubMed Web of Science ®Google Scholar
• WiseRADopamine, learning, and motivationNat Rev Neurosci2004548349415152198
   PubMed Web of Science ®Google Scholar
• WatkinsSSEpping-JordanMPKoobGFBlockade of nicotine self-administration with nicotinic antagonists in ratsPharmacol Biochem Behav19996274375110208381
   PubMed Web of Science ®Google Scholar
• PicciottoMRZoliMRimondiniRAcetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotineNature19983911731779428762
   PubMed Web of Science ®Google Scholar
• MarubioLMGardierAMDurierSEffects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptorsEur J Neurosci2003171329133712713636
   PubMed Web of Science ®Google Scholar
• WooltortonJRPidoplichkoVIBroideRSDifferential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areasJ Neurosci2003233176318512716925
   PubMed Web of Science ®Google Scholar
• PicciottoMRZoliMLénaCAbnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brainNature199537465677870173
   PubMed Web of Science ®Google Scholar
• XiZXSpillerKGardnerELMechanism-based medication development for the treatment of nicotine dependenceActa Pharmacol Sin20093072373919434058
   PubMed Web of Science ®Google Scholar
• CarrozziLPistelliFViegiGPharmacotherapy for smoking cessationTher Adv Respir Dis2008230131719124379
   PubMedGoogle Scholar
• SilagyCLancasterTSteadLNicotine replacement therapy for smoking cessationCochrane Database Syst Rev20043CD00014615266423
   PubMedGoogle Scholar
• LancasterTSteadLFMecamylamine (a nicotine antagonist) for smoking cessationCochrane Database Syst Rev20002CD00100910796584
   PubMedGoogle Scholar
• RoseJELevinEDConcurrent agonist-antagonist administration for the analysis and treatment of drug dependencePharmacol Biochem Behav1992412192261539072
   PubMed Web of Science ®Google Scholar
• RoseJEBehmFMWestmanECMecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment aloneClin Pharmacol Ther19945686998033499
   PubMed Web of Science ®Google Scholar
• ChildressARO’BrienCPDopamine receptor partial agonists could address the duality of cocaine cravingTrends Pharmacol Sci2000216910637646
   PubMed Web of Science ®Google Scholar
• CoeJWBrooksPRWirtzMC3, 5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessationBioorg Med Chem Lett2005154889489716171993
   PubMed Web of Science ®Google Scholar
• BarlowRBMcLeodLJSome studies on cytisine and its methylated derivativesBr J Pharmacol1969351611744387392
   PubMed Web of Science ®Google Scholar
• BenndorfSScharfenbergGKempeGSmoking withdrawal treatment with Cytisine (Tabex). Results of a semi-annual survey of former smokers after 4 weeks of therapyDtsch Gesundheitsw1970247747765524300
   PubMedGoogle Scholar
• ScharfenbergGBenndorfSKempeGCytisine (Tabex) as a pharmaceutical aid in stopping smokingDtsch Gesundheitsw1971264634654930772
   PubMedGoogle Scholar
• EtterJFLukasRJBenowitzNLCytisine for smoking cessation: a research agendaDrug Alcohol Depend2008923817825502
   PubMed Web of Science ®Google Scholar
• PapkeRLHeinemannSFPartial agonist properties of cytisine on neuronal nicotinic receptors containing the β2 subunitMol Pharmacol1994451421498302273
   PubMed Web of Science ®Google Scholar
• StolermanIPGarchaHSMirzaNRDissociations between the locomotor stimulant and depressant effects of nicotinic agonists in ratsPsychopharmacology (Berl)19951174304377604144
   PubMed Web of Science ®Google Scholar
• ReavillCWaltherBStolermanIPBehavioral andpharmacokinetic studies on nicotine, cytisine, and lobelineNeuropharmacology1990296196242385332
   PubMed Web of Science ®Google Scholar
• MuseoEWiseRAPlace preference conditioning with ventral tegmental injections of cytisineLife Sci199455117911867934614
   PubMed Web of Science ®Google Scholar
• ChandlerCJStolermanIPDiscriminative stimulus properties of the nicotinic agonist cytisinePsychopharmacology (Berl)19971292572649084064
   PubMed Web of Science ®Google Scholar
• RasmussenTSwedbergMDReinforcing effects of nicotinic compounds: intravenous self-administration in drug-naive micePharmacol Biochem Behav1998605675739632242
   PubMed Web of Science ®Google Scholar
• RollemaHChambersLKCoeJWPharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aidNeuropharmacology20075298599417157884
   PubMed Web of Science ®Google Scholar
• RollemaHCoeJWChambersLKRationale, pharmacology, and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessationTrends Pharmacol Sci20072831632517573127
   PubMed Web of Science ®Google Scholar
• CarrollFIYokotaYMaWSynthesis, nicotinic acetylcholine receptor binding, and pharmacological properties of 3′-(substituted phenyl) deschloroepibatidine analogsBioorg Med Chem20081674675417964169
   PubMed Web of Science ®Google Scholar
• SpillerKXiZXLiXVarenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in ratsNeuropharmacology200957606619393252
   PubMed Web of Science ®Google Scholar
• O’ConnorECParkerDRollemaHThe alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in ratsPsychopharmacology2009125 [Epub ahead of print]
   Web of Science ®Google Scholar
• SmithJWMoggATafiELigands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalize to the nicotine discriminative stimulus in the ratPsychopharmacology200719015717017115136
   PubMed Web of Science ®Google Scholar
• ZaniewskaMMcCrearyACStefan ′skiREffect of varenicline on the acute and repeated locomotor responses to nicotine in ratsSynapse20086293593918798299
   PubMed Web of Science ®Google Scholar
• MihalakKBCarrollFILuetjeCWVarenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptorsMol Pharmacol20067080180516766716
   PubMed Web of Science ®Google Scholar
• BrioniJDKimDJBO’NeillABNicotine cue: lack of effect of the alpha7 nicotinic receptor antagonist methyllycaconitineEur J Pharmacol1996301158773440
   PubMed Web of Science ®Google Scholar
• GommansJStolermanIPShoaibMAntagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6J miceNeuropharmacology2000392840284711044754
   PubMed Web of Science ®Google Scholar
• StolermanIPChamberlainSBizarroLThe role of nicotinic receptor alpha7 subunits in nicotine discriminationNeuropharmacology20044636337114975691
   PubMed Web of Science ®Google Scholar
• FaesselHMSmithBJGibbsMASingle-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokersJ Clin Pharmacol20064699199816920893
   PubMed Web of Science ®Google Scholar
• FaesselHMGibbsMAClarkDJMultiple-dose pharmacokinetics of the selective nicotine receptor partial agonist, varenicline, in healthy smokersJ Clin Pharmacol2006461439144817101743
   PubMed Web of Science ®Google Scholar
• FengBObachRSBursteinAHEffect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: An in vitro-in vivo studyClin Pharmacol Ther20088356757617971819
   PubMed Web of Science ®Google Scholar
• TsaiSTChoHJChengHSA randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokersClin Ther2007291027103917692719
   PubMed Web of Science ®Google Scholar
• GarrisonGDDuganSEVarenicline: a first-line treatment option for smoking cessationClin Ther20093146349119393839
   PubMed Web of Science ®Google Scholar
• NidesMOnckenCGonzalesDSmoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo-, and bupropion-controlledtrialwith1-yearfollow-upArchInternMed200616615611568
   Google Scholar
• OnckenCGonzalesDNidesMEfficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessationArch Intern Med20061661571157716908789
   PubMed Web of Science ®Google Scholar
• GonzalesDRennardSINidesMVarenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trialJAMA2006296475516820546
   PubMed Web of Science ®Google Scholar
• JorenbyDEHaysJTRigottiNAEfficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trialJAMA2006296566316820547
   PubMed Web of Science ®Google Scholar
• TonstadSTønnesenPHajekPEffect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trialJAMA2006296647116820548
   PubMed Web of Science ®Google Scholar
• NakamuraMOshimaAFujimotoYEfficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokersClin Ther2007291040105617692720
   PubMed Web of Science ®Google Scholar
• NiauraRHaysJTJorenbyDEThe efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trialCurr Med Res Opin2008241931194118513462
   PubMed Web of Science ®Google Scholar
• AubinHJBobakABrittonJRVarenicline versus transdermal nicotine patch for smoking cessation: results from a randomized openlabel trialThorax20086371772418263663
   PubMed Web of Science ®Google Scholar
• NidesMGloverEDReusVIVarenicline versus bupropion SR or placebo for smoking cessation: a pooled analysisAm J Health Behav20083266467518442345
   PubMed Web of Science ®Google Scholar
• WestRBakerCLCappelleriJCEffect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attemptPsychopharmacology (Berl)200819737137718084743
   PubMed Web of Science ®Google Scholar
• CahillKSteadLFLancasterTNicotine receptor partial agonists for smoking cessationCochrane Database Syst Rev200816CD00610318646137
   PubMed Web of Science ®Google Scholar
• MillsEJWuPSpurdenDEfficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysisHarm Reduct J200962519761618
   PubMed Web of Science ®Google Scholar
• WangCXiaoDChanKPPothiratCGarzaDDaviesSVarenicline for smoking cessation: a placebo-controlled, randomized studyRespirology20091438439219192221
   PubMed Web of Science ®Google Scholar
• WilliamsKEReevesKRBillingCBJrA double-blind study evaluating the long-term safety of varenicline for smoking cessationCurr Med Res Opin20072379380117407636
   PubMed Web of Science ®Google Scholar
• MooreTJCohenMRFurbergCDInstitute for Safe Medication PracticesStrong safety signal seen for new varenicline risks2008521 Available from: http://www.ismp.org/docs/vareniclinestudy.asp. Accessed 2008 May 29.
   Google Scholar
• Institute for Safe Medication Practices Quarter Watch (3rd Quarter 2008): Safety concerns with generics, Chantix aggressive behavior, and more. 2009 May 7. Available from: http://www.ismp.org/Newsletters/acutecare/articles/20090507.asp. Accessed 2010 March 29.
   Google Scholar
• US Food and Drug Administration Safety alerts for human medical products: Chantix (varenicline). 2007 November 20. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152098.htm. Accessed 2007 November 23.
   Google Scholar
• US Food and Drug Administration Public health advisory: important information on Chantix (varenicline). May 16, 2008. Available from: http://www.fda.gov/cder/drug/advisory/varenicline.htm. Accessed 2008 May 29.
   Google Scholar
• LyonGJPossible varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline personality disorder, and methamphetamine abuse in remissionJ Clin Psychopharmacol20082872072119011454
   PubMed Web of Science ®Google Scholar
• KintzPEvansJVillainMSmoking cessation with varenicline: a suicidal fatalityJ Anal Toxicol20093311812019239738
   PubMed Web of Science ®Google Scholar
• KutscherECStanleyMOehlkeKChantix-induced mental status changes in a young healthy femaleS D Med20096219319519489343
   PubMedGoogle Scholar
• PurvisTLMambourgSEBalvanzTMSafety and effectiveness of varenicline in a veteran population with a high prevalence of mental illnessAnn Pharmacother20094386286719383936
   PubMed Web of Science ®Google Scholar
• KasliwalRWiltonLVShakirSASafety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring studyDrug Saf20093249950719459717
   PubMed Web of Science ®Google Scholar
• US Dept of Transportation, Federal Motor Carrier Safety Administration Statement from administrator. 2008 May 23. Available from: http://www.fmcsa.dot.gov/statement-5-23-08.htm. Accessed 2008 May 28.
   Google Scholar
• Federal Aviation Administration Anti-smoking medicine Chantix banned. 2008 May 23. Available from: http://www.faa.gov/news/updates/index.cfm?newsld=56363. Accessed 2008 May 28.
   Google Scholar